In this study, researchers used the SEER-21 database to calculate 1-year cause-specific survival rates in patients diagnosed with a first primary malignant cancer between January 1, 2020, and December ...

In this phase 3 study, researchers sought to determine whether the addition of palbociclib may overcome resistance to endocrine and HER2-directed therapies.

Clinicians debunked common myths and misinformation regarding sunscreen necessity and safety that is gaining traction among young patients and online.

TEXT Treatment patterns and real-world survival outcomes varied by race/ethnicity, socioeconomic status, and practice setting in a cohort of women treated ...

Investigators sought to train and validate a machine learning model to distinguish paper mill publications from genuine articles and assess the prevalence of paper mill publications.

Conferences can be an excellent way to connect with fellow oncologists and stay informed on the latest research. These events are key to providing ...

Phase 3 trial data show datopotamab deruxtecan reduces the risk of disease progression or death in patients with metastatic TNBC.

Study researchers aimed to examine associations between financial hardship and self-reported pain among cancer patients initiating systemic treatment between April 2020 and August 2023.

Investigators assessed the relationship between risk for death and the consumption of ultra-processed foods after a cancer diagnosis, as well as whether chronic disease biomarkers are responsible.

Investigators conducted this phase III trial to determine whether immunotherapy was more effective when administered early in the day.

Investigators analyzed economic evaluations of adjuvant immunotherapy to assess cost-effectiveness outcomes, quality-adjusted life-year (QALY)/life-year (LY) gains, and methodologic approaches.

In this phase 2a study, researchers aimed to determine whether donor fecal microbiota transplantation improved survival in mRCC patients receiving immunotherapy.